12:00 AM
Apr 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dapsone: Began Phase II testing

Immune Network Research Ltd. (CDNX:IMM), Vancouver, B.C.
Product: Dapsone
Business: Neurological
Therapeutic category: Immune modulation
Target: Inflammatory enzymes
Description: Anti-inflammatory compound
Indication: Treat Alzheimer's...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >